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We have previously shown that treatment of Zucker rats and mice with diet-induced obesity with dietary
docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids in the form of krill oil reduces peripheral levels of
endocannabinoids, ectopic fat formation and hyperglycemia. We reported that such treatment reduces plasma
endocannabinoid levels also in overweight and obese human individuals, in whom high triglycerides may correlate
with high circulating endocannabinoid levels. In this study, we report the effects of krill powder, which contains
proteins (34%) in addition to krill oil (61.8%), on these two parameters. We submitted 11 obese men (average BMI
of 32.3 kg/m2, age of 42.6 years and plasma triglycerides of 192.5 ± 96.3 mg/dl) to a 24 week dietary
supplementation with krill powder (4 g/day per os) and measured anthropometric and metabolic parameters, as
well as blood endocannabinoid (anandamide and 2-arachidonoylglycerol) and esterified DHA and EPA levels. Six
subjects were included as control subjects and not given any supplements. The treatment produced, after 12 and
24 weeks, a significant increase in DHA and EPA in total plasma, a 59 and 84% decrease in anandamide plasma
levels, and a 22.5 and 20.6% decrease in triglyceride levels, respectively. There was also a significant decrease in
waist/hip ratio and visceral fat/skeletal muscle mass ratio at 24 weeks, but no change in body weight. These data
confirm that dietary krill powder reduces peripheral endocannabinoid overactivity in obese subjects, and might
ameliorate some parameters of the metabolic syndrome.
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Endocannabinoids are endogenous arachidonic acid
(AA)- and phospholipid (PL)-derived mediators that
activate the G-protein-coupled receptors for Δ9-tetrahydro-
cannabinol, known as cannabinoid receptors of type-1
(CB1) and −2 (CB2) [1]. Overactivation of CB1 receptors by
either of the two most studied endocannabinoids, i.e.
N-arachidonoyl-ethanolamine (anandamide, AEA) and
2-arachidonoylglycerol (2-AG), contributes to metabolic
dysfunctions in both obese rodents and humans [1].
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reproduction in any medium, provided the orat least in part a spillover from peripheral organs involved
in the control of lipid and glucose metabolism, are
elevated in obese subjects [2-4]. Plasma AEA levels are
sensitive to changes in the nutritional status, decreased
after a meal in lean and obese humans and reduced
by insulin infusion [2-4]. Plasma 2-AG levels, instead,
positively correlate with intra-abdominal obesity,
plasma triglyceride and markers of insulin resistance,
and negatively with HDL-cholesterol [5,6]. Weight loss in
intra-abdominally obese men is accompanied by reduced
AEA and 2-AG levels, and the decrease of the latter
correlates with weight loss-induced amelioration of high
triglycerides, insulin resistance and HDL-cholesterol levels
[7]. In mice, genetic deletion of the enzymes catalyzing
endocannabinoid hydrolysis, i.e. fatty acid amide hydrolase
and monoacylglycerol lipase, is followed by elevation oftd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Table 1 Composition of krill powder
% Content in
in powder 4 g krill powder (mg)
Proteins 34.0 1360
Total lipids 61.8 2472
Triglycerides 31.5 1260
Total PLs 25.4 1016
Total omega-3 13.7 548
Total omega-6 1.4 56
Saturated FAs 17.9 716
Total PUFAs 15.6 624
Total MUFAs 13.2 528
EPA 6.7 268
DHA 3.3 132
DHA: docosahexaenoic acid; EPA: eicosapentaenoic acid; FA: fatty acids; MUFAs:
monounsaturated fatty acids; PLs: phospholipids; PUFAs: polyunsaturated
fatty acids.
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of fatty acid amide hydrolase is accompanied by
increased body weight, and this phenotype is worsened by
the occurrence of increased adipose tissue and triglyceride
content in plasma, liver, skeletal muscle and adipose tissue
following a high fat diet (HFD) [8-10].
Whilst acute or chronic elevation of peripheral
endocannabinoid levels is accompanied by, and may
contribute to, metabolic disorders in obese animals and
human subjects, counteraction of CB1 activity with
selective inverse agonists or antagonists reduces obesity
and several ensuing metabolic disorders and counteracts
the dysmetabolic effects of a HFD in rodents [11]. Also
inhibition of the biosynthesis of endocannabinoids, namely
2-AG, can reduce food intake and body weight in rodents
fed with a HFD [12]. Recently, we have shown that yet
another strategy to reduce peripheral endocannabinoid
overactivity in obese rodents and overweight/obese humans
consists of the chronic supplementation with dietary
docosahexaenoic (DHA) and eicosapentaenoic (EPA) acids
in the form of krill oil [11,13-16]. In the case of Zucker rats
[15] and mouse made obese with a HFD [16], this strategy
was accompanied by a reduction of liver and heart ectopic
triglyceride levels or of HFD-induced hyperglycemia,
respectively. These effects were paralleled by the
expected reduction of AA esterified into PLs, and by
the finding of lower levels of AA-containing, direct
endocannabinoid biosynthetic precursors in these tissues.
Also in overweight/obese subjects the inhibitory effect of
krill oil on endocannabinoid levels was correlated to a
reduction of the n-6/n-3 long chain polyunsaturated fatty
acid (LCPUFA) ratio in plasma PLs [13]. Alvheim and
colleagues [17] recently showed that dietary linoleic acid
(LA), which is abundant in several western-type diets,
increases AA levels esterified into PLs, and, subsequently,
2-AG and AEA levels in the liver, and favors the
development of diet-induced obesity in mice in a
manner prevented by dietary EPA and DHA from fish
oil, which reduced the AA-PL pool and normalized
endocannabinoid tissue levels. These data indicate
that diets rich in n-3 LCPUFA, such as those provided by
fish or krill oil and krill powder supplementation, might
produce beneficial effects on the metabolic disorders
ensuing from a western type-like diet via reduction of
endocannabinoid biosynthesis in peripheral tissues.
This study was conducted in human obese individuals
to assess at the same time the effect of a krill preparation
on peripheral endocannabinoid levels and different
parameters of the metabolic syndrome. Twelve obese men
were submitted to a 24 week treatment with 4 g/day
(per os) of krill powder, which differs from krill oil
since it also contains proteins. We measured various
anthropometric and metabolic parameters, as well as
plasma AEA and 2-AG levels and the incorporationof AA, DHA and EPA in plasma PL, at baseline and
after 12 and 24 weeks. We also included in the study
six untreated age- and BMI-matched subjects. We report
that dietary krill powder reduces circulating AEA, but not
2-AG levels, and at the same time produces a beneficial
effect on high triglycerides.
Materials and methods
Study design
This was a single-centre, open label, pilot study to explore
effects of krill powder on overweight subjects. The study
was performed at Momentum Pharma Services GmbH
(Hamburg, Germany). Twelve subjects were given 4 g krill
powder daily as 500 mg gelatin capsules (active treatment
group) for 24 weeks. The krill powder capsules were
obtained from Aker BioMarine ASA (Oslo, Norway),
and the composition of the krill powder is shown in
Table 1. Six subjects were included as controls and
received no study products. All subjects included in
the study were males between 30 and 55 years, BMI
30–35 kg/m2, healthy and non-smoking. Subjects with
a known history or presence of a significant cardiovascular
disease, allergy towards crustaceans, bleeding disorders,
disturbed absorption due to changes in gastro-intestinal
tract, history of drug or alcohol abuse, contraindications of
an MRI procedure, or with a concomitant administration
of any medication which were known to be lipid
modifying agents, were excluded from the study. Active
treatment group had to oblige to restrictions which
included restriction of fatty fish or seafood meals (salmon,
mackerel, eel, halibut, trout, herring) to only once per week,
but not within 48 hours before clinic visits, prohibition of
functional food like cholesterol-reducing products and
lipid supplements.
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At the screening visit, demographic data, medical history,
diet, smoking and caffeine status was logged, and serology
tests, urine drug screen and an alcohol breath test were
performed. The screening was performed between 2 and
31 days before the treatment phase.
At all visits throughout the study (screening, week
0, 12, and 24), subjects had their body weight, waist-hip
ratio and body fat percentage measured. MRI scans (both
breath-hold and respiratory-triggered) were performed
and fasting glucose and insulin levels were measured
at week 0, 12 and 24. At all visits, blood for the
assessment of esterified fatty acids, lipids in serum
(total cholesterol, LDL-cholesterol, HDL-cholesterol,
triglycerides) and endocannabinoids were collected
from fasted subjects. Subjects in the control group
were only assessed for fasting endocannabinoid levels at
week 0, 12 and 24.
Safety assessments were performed at screening and
all visits in the study. Safety assessments included inquiry
about adverse events and concomitant medication at all
clinic visits and at phone calls (between all visits during
treatment), measurement of vital signs (blood pressure,
pulse rate, body temperature), physical examination, the
recording of a 12-lead ECG, and a standard clinical
laboratory assessment (urinalysis, haematology, clinical
chemistry).
Ethics
The study was conducted in compliance with the ethical
principles that have their origin in the Declaration of
Helsinki and that are consistent with Good Clinical
Practice (GCP), as described in Declaration of Helsinki
and ICH Harmonized Tripartite Guidelines for Good
Clinical Practice. The final protocol and the Informed
Consent Form (ICF) were approved by the Ethics
Committee of the Ärztekammer (Medical Chamber),
Hamburg, Germany.
The Investigator ensured that subjects were given
full and adequate oral and written information about
the nature, purpose, possible risks, and benefits
(comprehensive medical screening) of the study. Subjects
were also notified that they were free to discontinue their
participation in the study at any time. Subjects were given
time for consideration and to have the opportunity to ask
questions. The subject’s signed ICF was obtained before
conducting any procedure related to the study.
Body measurements
Subjects had their body weight, waist-hip ratio and body
fat percentage measured at Screening, baseline and 12
and 24 weeks (±1 week). Subjects were measured
barefoot in light underwear following manufacturer’s
instructions. The body fat percentage was measured usingBC-545 Segmental Body Composition Analyser (Tanita
Europe GmbH, Sindelfingen, Germany). This device uses
an 8 electrode segmental Bioelectrical Impedance Analysis
(BIA) to monitor multiple components of overall health.
Measurements included weight, body fat %, body water %,
muscle mass, and visceral fat rating. Manufacturers’
equations were used to predict body fat %, body
water %, muscle mass, and visceral fat rating.
Magnetic Resonance Imaging (MRI)
Abdominal body fat was measured by using the Siemens
Magnetom Avanto (76 × 18) Q-engine, SW B15 system.
MRI scans (both breath-hold and respiratory-triggered)
were performed at baseline and after 12 and 24 weeks of
treatment at Radiologische Praxis Altona (Hamburg,
Germany) by using the Dixon technique. The technique
acquires two separate images with a modified spin echo
pulse sequence. One is a conventional spin echo image
with water and fat signals in-phase and the other is
acquired with the readout gradient slightly shifted so that
the water and fat signals are 180 degrees out-of-phase.
From these two images, a water only image and a fat-only
image could was generated, and the availability of
both the water-only and fat-only images allowed
direct image-based water and fat quantitation. The
total volume of the target region was determined in
cm3 as an outcome [18].
Glucose, insulin and adiponectin measurements
For the fasting blood glucose and insulin assay, a 7.5 ml
serum monovette was used after being left 30 min standing
at room temperature and then centrifuged for 15 min at
2500xg at room temperature. The sample was divided in
aliquots sent ambient to Bioscientia (Hamburg, Germany)
for analysis of glucose and insulin.
Fatty acid analysis
Plasma samples were thawed in fridge overnight, vortexed,
centrifuged and pipetted into vials. Internal standard
(triheptadecanoin) is added and samples are methylated
with 3N MeOH HCl. FAMEs were extracted with hexane,
then samples are neutralized with 3N KOH in water. After
mixing and centrifuging the hexane phase is injected into
the GC-FID.
Analysis was performed on a 7890A GC with a
split/splitless injector, a 7683B automatic liquid sampler,
and flame ionization detection (Agilent Technologies,
Palo Alto, CA). Separations were performed on a SP-2380
(30 m × 0.25 mm i.d. × 0.25 μm film thickness) column
from Supelco.
Endocannabinoid analysis
Lipids were extracted from plasma (5 ml) and AEA and
2-AG pre-purified and quantified by isotope dilution- liquid
Table 2 Effect of krill powder supplementation on plasma
esterified fatty acid composition in obese men (N = 11) at
baseline, the middle and end of the study
Fatty acid Baseline Week 12 Week 24
C12:0 0.10 ± 0.05 0.12 ± 0.07 0.12 ± 0.11
C14:0 1.25 ± 0.41 1.18 ± 0.41 1.19 ± 0.56
C15:0 0.20 ± 0.04 0.19 ± 0.04 0.20 ± 0.05
C16:0 23.27 ± 2.53 22.28 ± 2.41 22.78 ± 3.10
C16:1 2.49 ± 0.52 2.03 ± 0.59 ** 2.19 ± 0.82
C18:0 6.56 ± 0.37 6.45 ± 0.46 6.42 ± 0.41
C18:1,t6-11 0.35 ± 0.13 0.47 ± 0.32 0.35 ± 0.14
C18:1,c9 23.10 ± 2.54 22.06 ± 2.05 21.54 ± 2.21 **
C18:1,c11 1.56 ± 0.29 1.52 ± 0.21 1.56 ± 0.25
C18:2,n-6 23.11 ± 3.78 25.25 ± 4.06 ** 24.37 ± 4.99
C20:0 0.25 ± 0.05 0.25 ± 0.04 0.25 ± 0.05
C18:3,n-6 0.45 ± 0.18 0.37 ± 0.09 0.35 ± 0.09
C18:3,n-3 0.73 ± 0.30 0.75 ± 0.26 0.73 ± 0.19
C20:1,n-9 0.15 ± 0.05 0.15 ± 0.04 0.16 ± 0.04
C20:2,n-6 0.19 ± 0.04 0.18 ± 0.03 0.17 ± 0.04
C22:0 0.56 ± 0.13 0.60 ± 0.14 0.60 ± 0.16
C20:3,n-6 1.51 ± 0.21 1.33 ± 0.17 * 1.38 ± 0.15 *
C20:4,n-6 (AA) 4.85 ± 1.15 5.00 ± 0.78 5.30 ± 1.13
C20:4,n-3 0.10 ± 0.04 0.10 ± 0.03 0.09 ± 0.03
C20:5,n-3 (EPA) 0.75 ± 0.24 1.24 ± 0.20 *** 1.15 ± 0.43 ***
C24:0 0.54 ± 0.15 0.54 ± 0.16 0.54 ± 0.16
C24:1 1.00 ± 0.30 1.02 ± 0.19 1.04 ± 0.29
C22:5,n-3 0.47 ± 0.08 0.53 ± 0.08 * 0.52 ± 0.08 *
C22:6,n-3 (DHA) 1.37 ± 0.32 1.67 ± 0.37 * 1.72 ± 0.28 ***
Data are expressed as mean g/100g FAME in plasma ± S.D. P-value was
calculated at week 12 and 24 vs. baseline using a paired T-test. *, P < 0.05;
**, P < 0.01; ***, P < 0.005 vs baseline.
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mass spectrometry (LC-APCI-MS) as described previ-
ously [19-21]. Also the endogenous AEA congeners,
palmitoylethanolamide (PEA) and oleoylethanolamide
(OEA), were measured using the same methods, and
as described previously [19]. Data were analyzed as the
means of the percent changes from baseline (beginning of
study) levels.
Statistical analysis
For statistical testing, a paired T-test was used. The
12 and 24 week measurements were tested against
baseline values. Significance levels were set to P < 0.05.
All statistical tests were performed with JMP 10.0.2
(SAS Institute).
Results
One subject in the active treatment group was excluded
from the analysis, since he was lost to follow-up in the
middle of the study. A number of 11 subjects in the
active treatment group and all 6 subjects in the control
group completed the study. There were no major protocol
deviations or serious adverse events in the study, and the
study product was well tolerated.
Dietary supplementation with 4 g/day (per os) of krill
powder produced a significant increase in esterified
DHA and EPA after both 12 and 24 weeks (P < 0.05)
(Table 2). Therefore, percent wise, there was a reduction
in the levels of esterified AA (as well as other fatty acids)
relative to DHA and EPA (Table 2). Krill powder also
produced: 1) a ~22.5 and 20.6% decrease in triglycerides
levels after 12 and 24 weeks, respectively, although this
was statistically significant (P < 0.05) only at 24 weeks
(Table 3), and 2) a ~2.9% decrease in waist/hip ratio, also
statistically significant at 24 weeks. No effect on any of
the other metabolic or biochemical parameters was
observed. Krill powder supplementation also produced a
non-statistically significant, time-dependent trend
towards decreased visceral fat, measured by the 3D
three-point Dixon MRI, at both 12 and 24 weeks
(Table 3). Interestingly, this trend became significant
at 24 weeks if normalized by the percent change in skeletal
muscle mass (Table 3). Eight subjects out of 11 showed
slight reductions in the measured abdominal body fat (not
shown). Slight increases were noticed in mean values of
total muscular mass as well as total water content after 24
weeks of active treatment. In addition, mean computed
integral liver fat peak value, measured by the Proton liver
SVS, also showed non-statistically significant reductions
from baseline to week 24 (Table 3). At week 12, 4 subjects
showed a decrease in the measured liver density, whereas 5
subjects showed a decrease in the measured liver density at
week 24 (not shown). There was no effect on body weight
at any time point.Concomitantly to these changes, krill powder supple-
mentation produced a 59 and 84% statistically significant
decrease in AEA plasma levels at 12 and 24 weeks,
respectively (Figure 1). There was also a statistically
significant, albeit smaller, decrease in PEA and OEA
levels. The levels of 2-AG were not altered (Figure 1).
No change in the levels of these compounds in the
control group was observed at any time point (data
not shown). No statistically significant correlation was
found between endocannabinoid, OEA or PEA and
triglyceride levels at any time.
Discussion
We have reported here that dietary supplementation to
obese men of DHA and EPA, in the form of krill powder,
efficiently and persistently reduces high triglycerides
independently from any overall effect on body weight, and
at the same time lowers plasma AEA levels, i.e. a marker of
Table 3 Biochemical and anthropometric measures of the
volunteers (N = 11) at baseline, the middle and end of
the study
Parameter Baseline Week 12 Week 24
Cholesterol (mg/dL) 210.3 ± 27.7 203.0 ± 39.5 206.3 ± 40.8
HDL (mg/dL) 45.1 ± 9.5 43.2 ± 10.5 43.6 ± 9.8
LDL (mg/dL) 139.1 ± 24.2 133.0 ± 28.6 137.9 ± 33.6
Triglycerides (mg/dL) 192.6 ± 96.3 149.3 ± 70.5 152.8 ± 96.2 *
VAT (L) 16.73 ± 2.55 16.29 ± 3.13 16.15 ± 2.42
Liver density (integral) 84.3 ± 79.2 79.2 ± 91.5 69.2 ± 74.6
Insulin (uU/ml) 15.5 ± 14.4 18.7 ± 11.9 17.4 ± 9.1
Glucose (mg/dL) 96.7 ± 13.6 99.6 ± 13.0 101.2 ± 18.4
Body fat (%) 28.4 ± 2.9 28.0 ± 3.1 27.9 ± 2.9
Weight (kg) 103.8 ± 12.6 104.0 ± 13.7 104.0 ± 13.4
Muscular mass (kg) 70.6 ± 8.9 71.1 ± 9.3 71.3 ± 9.1
Water (%) 50.8 ± 2.7 51.1 ± 2.8 51.3 ± 2.5
Waist/hip ratio 1.01 ± 0.04 0.99 ± 0.07 0.98 ± 0.05 *
VAT/muscular mass ratio 0.24 ± 0.04 0.23 ± 0.04 0.23 ± 0.03 *
Body fat/muscular mass ratio 0.41 ± 0.08 0.40 ± 0.08 0.40 ± 0.07
VAT: visceral adipose tissue. P-value was calculated at week 12 and 24 vs.
baseline using a paired T-test. * P-value < 0.05 vs baseline.
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overactivation, to obesity-associated dysmetabolism [1].
The effect of krill powder on high triglyceride levels
appeared to be maximal already after 12 weeks of
supplementation, and persisted until the end of the
study, i.e. at 24 weeks. This suggests that this effect
was of a relatively rapid onset, sustained and not merely
due to subjects undergoing periodic medical control.Figure 1 Effect of 4 g daily krill powder supplementation on
plasma anandamide (AEA), 2-arachidonoyl-glycerol (2-AG),
palmitoylethanolamide (PEA) and oleoylethanolamide (OEA)
levels in obese men after 12 and 24 weeks (N = 11). *, P < 0.05;
**, P≤ 0.01; ***, P < 0.005 vs baseline (paired t-test).Unlike triglycerides, the effect on plasma levels of the
endocannabinoid AEA was already significant after 12
weeks, but was maximal after 24 weeks of supplementation.
Thus, possibly also due to the relatively low number of
subjects recruited for this study, no correlation was
found between plasma AEA and triglyceride levels,
either before, in the middle or at the end of the diet-
ary supplementation. Interestingly, previous studies
showed that, of the two endocannabinoids, AEA and
2-AG, it is rather the plasma levels of the latter com-
pound that, in overweight/obese individuals, directly
correlate with plasma triglycerides, as well as with
other anthropometric and metabolic parameters, such
as visceral adipose tissue, insulin resistance and low
HDL-cholesterol [5,6]. Furthermore, weight loss in ab-
dominally obese men after one year of lifestyle (cal-
oric restriction and exercise) intervention caused a
reduction of the levels of both AEA and 2-AG, but only
the latter: 1) correlated with weight loss-induced reduction
in visceral adipose tissue, plasma triglycerides, insulin
resistance and low HDL-cholesterol, and 2) through
multivariate analyses was found to be an independent
predictor of some of the observed reduction in plasma
triglycerides [21].
Krill powder supplementation in this study: 1) reduced
AEA, but not 2-AG, levels, this effect becoming maximal
after the effect on triglyceride levels; and 2) produced
only a trend towards the reduction of intra-abdominal
fat. Therefore, it is tempting to speculate that krill oil-
induced reduction of AEA levels is an effect that either
occurs independently from the effect on triglycerides, or
contributes, via reduced CB1 activation in peripheral
organs, only to the sustained reduction of triglyceride
levels. On the other hand, it was surprising to find that a
reduction in plasma triglyceride levels (~20-22%) similar to
the one (22.2%) previously shown [21] to be accompanied
by reduced 2-AG levels, did not produce a similar effect in
the present study, despite the fact that, as mentioned above,
2-AG is considered an independent predictor of at least
part of plasma triglyceride levels in intra-abdominally obese
men. It is possible that such correlation holds true only
after weight loss, an effect not observed here, or following
stronger reductions in intra-abdominal fat, or only in
intra-abdominally obese men, as were the subjects of the
previous study (who exhibited an average BMI of ~30 at
the beginning of the study). Alternatively, it is also possible
that the low number of obese men who underwent krill
powder treatment (n = 11), a limitation of the present
study, or the shorter duration of the present treatment as
compared to the 1 year lifestyle intervention used in
the previous study [20], prevented us from observing
a reduction in 2-AG levels. However, it must be pointed
out that a statistically significant, albeit small, effect on
waist/hip ratio and visceral fat (if normalized to skeletal
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former effect is in agreement with the previous finding of
an association between high plasma AEA levels and waist
circumference in mixed gender (predominantly female)
non-obese and obese cohorts with average BMI of 21 and
42, respectively [3].
Whilst dietary supplementation of DHA and EPA in
the form of fish oil had been already shown to reduce
triglycerides in human subjects with signs of the
metabolic syndrome [22-26], before the present report no
such human data existed with regard to krill preparations.
Importantly, in order to obtain a decrease of triglycerides
similar to that found in the present study, higher doses of
EPA plus DHA (3–4 g/day) in the form of fish oil are
required [27]. It has been claimed that fish oil exerts its
effect through PPARα activation in the liver by DHA, thus
strongly increasing fatty acid β-oxidation and reducing
hepatic triglyceride formation and release [28]. Krill oil
and krill powder, however, differ from fish oil as they
contain DHA and EPA mostly esterified to PLs rather
than triglycerides. More than 80% of the EPA and DHA in
krill oil/krill powder are associated with PLs, and the
remaining is in triglyceride form [29]. Interestingly, both
dietary krill oil and n-3 LCPUFAs supplemented as PLs
were recently shown to produce stronger beneficial
effects than fish oil or n-3 LCPUFAs supplemented as
triglycerides, respectively, on ectopic triglyceride accumula-
tion, inflammation and other metabolic dysfunctions in
obese Zucker rats and DIO mice [15,30]. In these previous
animal studies, krill oil or n-3 LCPUFAs supplemented as
PLs were also found to be more effective at reducing
endocannabinoid levels in peripheral organs, and, in Zucker
rats, a stronger effect was found on AEA rather than 2-AG
levels [15,29]. On the other hand, in a cohort of mostly
women with average BMI of ~31, administered with dietary
krill oil at a dose of 2.5 g/day, the endocannabinoid
the plasma levels of which were reduced after 4
weeks treatment was 2-AG and not AEA. This effect
was more efficacious than with an n-3 LCPUFA-equivalent
amount of fish oil, which, in fact, did not produce
any effect [13]. Therefore, it is possible that treatments with
different formulations of krill oil, in different cohorts of
subjects, and for a shorter duration, may produce different
effects on plasma endocannabinoid levels. However,
regardless of the type of formulation, protocol of adminis-
tration and subjects or animal model of obesity undergoing
the supplementation, the effect of krill oil on the peripheral
levels of AEA and/or 2-AG is always accompanied by
a reduction in the levels of esterified AA relative to
EPA and DHA levels. This effect was observed also in
the present study and we hypothesize that it may lead
to an overall reduction of AEA biosynthetic precursor,
N-arachidonoyl-phosphatidylethanolamine, which in
turn would be responsible for the observed reductionin plasma AEA levels. Indeed, in the previous study in
which n-3 LCPUFAs were supplemented as PLs to DIO
mice [30], the reduction in white adipose tissue AEA levels
was found to be accompanied by an equivalent elevation of
the levels of its DHA- and EPA-derived congeners.
Therefore, rather than, or in addition to, activation of
PPARα, dietary EPA and DHA, especially in the form of
krill preparations, might produce their effects on fasting
triglycerides in obesity by re-equilibrating endocannabinoid
levels and CB1 receptor tone. Interestingly, a decrease of
the LCPUFA n-6/n-3 ratio in the plasma of hypercholester-
olemic and overweight subjects, obtained with a different
dietary intervention, was recently reported to be still
accompanied by a 40% decrease in plasma AEA
levels, but to be associated, instead, with a significant
decrease of LDL-cholesterol [31]. Moreover, krill powder
also contains astaxanthin which could theoretically cause
biological effects, but the concentration is believed to be
too low to be of any relevance (approximately 200 μg
in 4 g krill powder).
It was interesting to find here how the levels of two
AEA-related metabolites, OEA and PEA, changed in the
same direction as AEA following dietary krill powder
supplementation. These two compounds are inactive at
cannabinoid receptors but can stimulate peroxisome
proliferator-activated receptor-α and transient receptor
potential vanilloid type-1 channels [19], two lipid-sensitive
proteins which have been involved in the control of
metabolism. In a previous study in human lean, obese and
type 2 diabetes obese subjects, the plasma levels of AEA,
OEA and PEA were found to correlate with each other
[18], which is not surprising since these three compounds
share similar, although not fully overlapping, biosynthetic
and degrading routes and enzymes (see [18,19] and
references cited therein). Therefore, we hypothesize
that the small but significant reduction in the plasma
levels of PEA and OEA might be due not only to the
decrease of esterified palmitic and oleic acid relative
to DHA and EPA, but also to alterations in the expression
of their metabolic enzymes, as previously observed in
osteoblasts [32], and that this might have contributed
also to AEA, but not 2-AG, level reduction.
In conclusion, we have shown here that dietary supple-
mentation with a krill powder persistently ameliorates high
triglycerides without weight loss in obese men, to an extent
similar to that observed following lifestyle-induced weight
loss in a previous study in dyslipidemic overweight/obese
men [21], and in a shorter period of time (12–24 weeks vs.
one year). The understanding of whether or not this
metabolic effect of dietary DHA and EPA is due to
its concomitant reduction of plasma AEA levels, i.e. a
potential index of peripheral CB1 receptor activity in
humans, and of its subsequent action on lipid metabolism
and triglyceride clearance evidenced in rodents [9,10], will
Berge et al. Lipids in Health and Disease 2013, 12:78 Page 7 of 8
http://www.lipidworld.com/content/12/1/78probably require further investigations with larger cohorts
of subjects, varying doses of krill powder and several
different time points. At any rate, given the ever
increasingly established role of high triglycerides as an early
determinant of insulin resistance, type 2 diabetes,
atherosclerosis and cardiovascular risk in overweight
and obese subjects, the present data suggest that dietary
krill powder supplementation might represent a novel
preventive strategy for these disorders.
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